I think you overstepped there. First of all, this is a case report. You have been an ER doctor long enough to know that case reports are very common in the medical field. Although case reports are not clinical trials, they are very important in driving the medical field forward and discover new treatments. If you are only allowed to treat patients based on the use of medications for their approved conditions, what are you going to give to patients with an unknown diagnosis or idiopathic diseases?
As far as I know, Doctors do 'experiments' on real patients based on their best judgement and experiences and use treatments that Do not harm the patients. So it is better for all doctors to publish case reports, just like the authors of this paper. All they are saying is, MSCs look interesting and so far the result is encouraging (here is the evidence), one should look into it further.
- Forums
- ASX - By Stock
- MSB
- Ann: Remestemcel-L for COVID-19 MIS-C published in Pediatrics
Ann: Remestemcel-L for COVID-19 MIS-C published in Pediatrics, page-161
-
-
- There are more pages in this discussion • 263 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.17 |
Change
-0.025(2.10%) |
Mkt cap ! $1.370B |
Open | High | Low | Value | Volume |
$1.18 | $1.22 | $1.17 | $2.868M | 2.407M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
14 | 41580 | $1.17 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.17 | 22653 | 10 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
13 | 44471 | 1.165 |
16 | 125573 | 1.160 |
9 | 146106 | 1.155 |
13 | 440061 | 1.150 |
3 | 16785 | 1.145 |
Price($) | Vol. | No. |
---|---|---|
1.170 | 14865 | 6 |
1.175 | 27727 | 9 |
1.180 | 62713 | 10 |
1.185 | 58570 | 8 |
1.190 | 18205 | 5 |
Last trade - 12.10pm 15/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |